Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Common Equity (2016 - 2026)

Summit Therapeutics filings provide 13 years of Common Equity readings, the most recent being $545.9 million for Q1 2026.

  • Quarterly Common Equity rose 58.55% to $545.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $545.9 million through Mar 2026, up 58.55% year-over-year, with the annual reading at $658.9 million for FY2025, 69.48% up from the prior year.
  • Common Equity hit $545.9 million in Q1 2026 for Summit Therapeutics, down from $658.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $658.9 million in Q4 2025 and bottomed at $44.2 million in Q1 2024.
  • Average Common Equity over 5 years is $227.8 million, with a median of $133.5 million recorded in 2023.
  • The largest annual shift saw Common Equity crashed 66.88% in 2024 before it surged 678.85% in 2025.
  • Summit Therapeutics' Common Equity stood at $126.7 million in 2022, then crashed by 38.66% to $77.7 million in 2023, then surged by 400.37% to $388.7 million in 2024, then skyrocketed by 69.48% to $658.9 million in 2025, then dropped by 17.14% to $545.9 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Common Equity are $545.9 million (Q1 2026), $658.9 million (Q4 2025), and $192.3 million (Q3 2025).